News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

Kevin Schwartz, MD, MSc, FRCPC

Advertisement

Articles by Kevin Schwartz, MD, MSc, FRCPC

"Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

ByBradley Langford, PharmD, BCPS*,Jennifer Lo, PharmD,Kevin Schwartz, MD, MSc, FRCPC
October 15th 2019

By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.

Advertisement

Latest Updated Articles

  • "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure
    "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

    Published: October 15th 2019 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

Dynavax and Vaxart Partner to Advance Oral COVID-19 Vaccine

2

Using Doxycycline for Post-Exposure Prevention of Lyme Disease in Young Kids

3

FDA Clears Immuron’s IMM-529 For Clinical Testing in C difficile; Phase 2 Set to Begin in Australia

4

Clesrovimab Lowers RSV Hospitalizations and Illness in Healthy Infants

5

Streamlining Care Models Key to Managing Skin and Soft Tissue Infections

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us